Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v1-EN
Language French English
Date Updated 2019-04-18 2019-04-02
Drug Identification Number 02453819 02453819
Brand name PRALUENT PRALUENT
Common or Proper name Praluent Pen 75mg/mL Praluent Pen 75mg/mL
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients ALIROCUMAB ALIROCUMAB
Strength(s) 75MG 75MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 2 pre-filled pens 2 pre-filled pens
ATC code C10AX C10AX
ATC description LIPID MODIFYING AGENTS, PLAIN LIPID MODIFYING AGENTS, PLAIN
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2019-04-15 2019-04-15
Actual start date
Estimated end date 2019-05-06 2019-05-06
Actual end date 2019-04-17
Shortage status Resolved Anticipated shortage
Company comments TEMPORARY SHORTAGE OF PRALUENT, 75mg/mL & 150mg/mL (Alirocumab) We recognize the difficulties that this situation may cause for patients and health care providers. We apologize for any inconvenience resulting from this. Please note that both strengths (75 mg/mL and 150mg/mL) are not equivalent. For more information, please contact your healthcare professional. All efforts are being made to resolve the situation and any update will be communicated on the www.drugshortagescanada.ca website. TEMPORARY SHORTAGE OF PRALUENT, 75mg/mL & 150mg/mL (Alirocumab) We recognize the difficulties that this situation may cause for patients and health care providers. We apologize for any inconvenience resulting from this. Please note that both strengths (75 mg/mL and 150mg/mL) are not equivalent. For more information, please contact your healthcare professional. All efforts are being made to resolve the situation and any update will be communicated on the www.drugshortagescanada.ca website.
Health Canada comments